New Atlas15m
US approves "milestone" Parkinson's treatment for 2025 release
Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.
MedPage Today11h
FDA OKs New Wearable Treatment for Parkinson's Disease
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...
TMCnet17h
Supernus Announces FDA Approval of ONAPGOâ„¢ (apomorphine hydrochloride) for Parkinson's Disease
USE ONAPGO is a prescription medicine used to treat motor fluctuations (OFF episodes) in adults with advanced Parkinson’s disease (PD). It is not known if ONAPGO is safe and effective in children.
Dopamine doesn’t actually make you feel good—here's the science behind the 'happy hormone'
Dopamine rushes, withdrawals, and detoxes are trending among wellness gurus online. But experts say the science behind the ...
The American Journal of Managed Care10h
FDA Approves First Subcutaneous Apomorphine Device for Parkinson Disease
The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...
The Lancet7h
First phase 3 trial of GLP-1 receptor agonist for neurodegeneration
The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...